Results 91 to 100 of about 119,167 (297)

Effects of Treatment with Glucagon-like Peptide-1 Receptor Analogues on the Diabetic Foot

Biomedicines
Background/Objectives: Diabetic foot disease is one of the most severe and disabling complications of type 2 diabetes mellitus, resulting from the interaction between peripheral neuropathy, peripheral arterial disease, and infection.
Mercedes Ortiz Romero, David Rodríguez de Vera Gómez, Pablo Rodríguez de Vera Gómez, Luis María Gordillo Fernández   +3 more
doaj   +1 more source

SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels [PDF]

, 2019
学位記番号 ...
Suga, Takayoshi, スガ, タカヨシ, 須賀, 孝慶   +2 more
core  

Anti‐Obesity Pharmacotherapy and Emerging Multimodal Interventions for Obstructive Sleep Apnea

Chronic Diseases and Translational Medicine, EarlyView.
Cellular and molecular mechanisms of obesity‐related obstructive sleep apnea (OSA). ADMA: asymmetric dimethyrarginine, NLRP3: nucleotide‐binding domain, leucine‐rich repeat family, Pyrin domain containing 3, TLR: toll‐like receptors, IL‐1β: interleukin‐1β, IL‐6: interleukin‐6; LPS: lipopolysacharide, ROS: reactive oxygen species, TNF‐α.
Anish Preshy, Cornelius J. Fernandez, Mohammad Hamid Nedai, Joseph M. Pappachan   +3 more
wiley   +1 more source

Gut Hormones and Inflammatory Bowel Disease

Biomolecules
Obesity-driven inflammation disrupts gut barrier integrity and promotes inflammatory bowel disease (IBD). Emerging evidence highlights gut hormones—including glucagon-like peptide-1 (GLP-1), glucagon-like peptide-2 (GLP-2), glucose-dependent ...
Jonathan Weng, Chunmin C. Lo
doaj   +1 more source

Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes

Сахарный диабет, 2017
Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) are a class of antidiabetic drugs developed over the past 15 years. GLP-1, a gastrointestinal peptide hormone that contributes to the postprandial “incretin effect”, stimulates ...
Gagik R. Galstyan, Evgeniya A. Karataeva, Ekaterina A. Yudovich   +2 more
doaj   +1 more source

c-Fos induction by gut hormones and extracellular ATP in osteoblastic-like cell lines [PDF]

, 2016
It is widely accepted that the c-Fos gene has a role in proliferation and differentiation of bone cells. ATP-induced c-Fos activation is relevant to bone homeostasis, because nucleotides that are present in the environment of bone cells can contribute to
A Gartland, A Liedert, A Trümper, AE Grigoriadis, BM Wice, C Kaebisch, C Meier, CJ Dixon, D Xie, DB Henriksen, DB Henriksen, DB Henriksen, DJ Drucker, E Velázquez, EL Pacheco-Pantoja, Elda Leonor Pacheco-Pantoja, IR Orriss, IR Orriss, J Kim, J Parker, James A. Gallagher, Jane P. Dillon, JE Koch, JV Zhang, KA Buckley, M-C Beauvieux, MC Bunck, MJ Hayton, Peter J. M. Wilson, RJ Bollag, S Sasaki-Hamada, S Sasaki-Hamada, S Susini, T Inhoff, T Tsuboi, WB Bowler, William D. Fraser   +36 more
core   +1 more source

Frailty and Cardiovascular Events as Determined by Body Composition: A Systematic Review

Chronic Diseases and Translational Medicine, EarlyView.
Frailty phenotypes and risk of cardiovascular disease. Sarcopenic obese phenotype is associated with increased prevalence of cardiovascular risk factors and progression of metabolic syndrome, leading to cardiovascular events and cardiovascular mortality, while the Anorexic malnourished phenotype is associated with reduced prevalence of cardiovascular ...
Ishleen Oberoi, Shabnam Tariq, Kristian Arak, Mhd Alaa Aldin Al‐Haffar, Kyaw Thet, Ahmed H. Abdelhafiz   +5 more
wiley   +1 more source

Obesity Treatments to Improve Type 1 Diabetes (OTID): a randomized controlled trial of the combination of glucagon-like peptide 1 analogues and sodium-glucose cotransporter 2 inhibitors—protocol for Obesity Treatments to Improve Type 1 Diabetes (the OTID trial)

Trials
Background The guidelines of the American Diabetes Association and European Association for the Study of Diabetes suggest that patients with obesity type 2 diabetics and chronic kidney disease need either glucagon-like peptide 1 receptor analogues or ...
Ebaa Al-Ozairi, Kavita Narula, Alexander D. Miras, Etab Taghadom, Abeer El Samad, Jumana Al Kandari, Anas Alyosef, Anant Mashankar, Werd Al-Najim, Carel W. le Roux   +9 more
doaj   +1 more source

Effect of Oral Nutritional Supplements with Sucromalt and Isomaltulose versus Standard Formula on Glycaemic Index, Entero-Insular Axis Peptides and Subjective Appetite in Patients with Type 2 Diabetes: A Randomised Cross-Over Study [PDF]

, 2019
Oral diabetes-specific nutritional supplements (ONS-D) induce favourable postprandial responses in subjects with type 2 diabetes (DM2), but they have not been correlated yet with incretin release and subjective appetite (SA).
Angarita Dávila, Lisse Chiquinquira, Aparicio, Daniel, Bermúdez Pirela, Valmore José, Cisternas, Silvia, Costa, Jorge de Assis, Céspedes, Virginia, Durán-Agüero, Samuel, Escobar, M. Cristina, López-Miranda, José, Reyna Villasmil, Nadia Yra, Rojas-Gómez, Diana   +10 more
core   +2 more sources

GLP‐1 Receptor Agonists in Metabolic Dysfunction‐Associated Steatotic Liver Disease: Bridging Hepatic and Cardiovascular Outcomes

Chronic Diseases and Translational Medicine, EarlyView.
Endogenous GLP‐1 and exogenous GLP‐1 RAs activate GLP‐1R‐expressing vagal afferents in the portal vein, projecting to the nucleus tractus solitarius (NTS). This input engages brainstem–hypothalamic circuits that regulate metabolic homeostasis. Hypothalamic efferent vagal output to the liver suppresses lipogenesis, enhances triglyceride export, and ...
Gabriel Amorim Moreira Alves, Masatoki Teranishi, Rajendranandini Majumdar, Fazal Khan, Mohan Dodeja, Ana Claudia Teixeira de Castro Gonçalves Ortega, Marco Acerboni, Arosh S. Perera Molligoda Arachchige, Frank James   +8 more
wiley   +1 more source